Abstract
BackgroundTwo studies (PDY14191 [NCT02404558]: randomised, open-label, Japanese patients; 6R88-RA-1309 [NCT02097524]: randomised, open-label, non-Japanese patients) assessed the pharmacodynamic profiles of two monoclonal antibody blockers of IL-6Rα, sarilumab and tocilizumab.ObjectivesTo evaluate the...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
